Aegon NV (0Q0Y)
London Stock Exchange · UK · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 7.335 |
|---|---|
| 52-week range | 5.776 – 8.367 |
| Return, 1 month / 3 months | −6.6% / −6.9% |
| Return, 1 year / 3 years | +19.9% / +92.0% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 38 |
| Volatility (1 year) | 23.4% |
| Worst drawdown (1 year) | -14.0% |
| Average daily value traded | 12.50M EUR |
| Dividend yield | 5.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Aegon is an international insurance and asset management company based in the Netherlands. It offers life insurance, pensions, savings and investment products to individual customers and to businesses, and its asset management business manages investments for institutional and retail clients. The company operates across Europe, the Americas and Asia, serving customers through its insurance brands and investment management arm. Aegon's activities centre on helping people and institutions protect their finances and save for retirement.
On this site Aegon NV appears as a stock on the London Stock Exchange (UK), code 0Q0Y, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Aegon NV (0Q0Y) trades on the London Stock Exchange in UK. It last closed at EUR 7.335 on 27 October 2026.
Its price-based Market X-Ray is 71 out of 100 (a strong price profile), ranking 470 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 19.9% and over the last three months it fell 6.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 70 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 5.2% | ||
| From 52-week high | -11.6% | ||
| Momentum | 61 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -6.9% | ||
| 6-month return | 12.5% | ||
| 12-month return, skipping the last month | 28.3% | ||
| Stability (higher is calmer) | 84 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 23.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -14.0% | ||
| Liquidity | 76 · Strong | Trades actively. | |
| Average daily value traded | 12.50M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 62 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 5.7% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −0.5% |
|---|---|
| 1 month | −6.6% |
| 3 months | −6.9% |
| 6 months | +12.5% |
| 1 year | +19.9% |
| 3 years | +92.0% |
| 5 years | +115.6% |
Signals
| 50-day / 200-day average | 7.693 / 6.974 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.096 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Sep 2026 | EUR 0.2100 |
| 12 Jun 2026 | EUR 0.2100 |
| 3 Sep 2025 | EUR 0.1900 |
| 16 Jun 2025 | EUR 0.1900 |
| 4 Sep 2024 | EUR 0.1600 |
| 14 Jun 2024 | EUR 0.1600 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.